|
FY2025
12 months to Dec 31, 2025
|
FY2024
12 months to Dec 31, 2024
|
FY2023
12 months to Dec 31, 2023
|
FY2022
12 months to Dec 31, 2022
|
FY2021
12 months to Dec 31, 2021
|
|
|---|---|---|---|---|---|
| Operating expenses: | |||||
| Research and development | |||||
| General and administrative | |||||
| Total operating expenses | |||||
| Loss from operations | |||||
| Other income | |||||
| Change in fair value of warrant liability | |||||
| Loss on extinguishment of debt | |||||
| Interest income | |||||
| Net loss | |||||
| Deemed dividend on Series B Warrants | |||||
| Net loss available to common stockholders | |||||
| Net loss per share of common stock, basic (in usd per share) | |||||
| Net loss per share of common stock, diluted (in usd per share) | |||||
| Weighted-average common shares outstanding, basic (in shares) | |||||
| Weighted-average common shares outstanding, diluted (in shares) | |||||
Loading...